IM-412 inhibits transforming growth factor β-induced fibroblast differentiation in human lung fibroblast cells

Biochemical and Biophysical Research Communications

Volumn 399, Issue 2, 2010, Pages 268-273

  Park, Sarah ^a,b   Ahn, Ji Yeon ^a   Lim, Min Jin ^a   Kim, Mi Hyoung ^a   Lee, Sae Lo Oom ^a   Yun, Yeon Sook ^a   Jeong, Gajin ^b   Song, Jie Young ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Anti fibrosis; Fibroblast; Myofibroblast; TGF

Indexed keywords

3 (2 CHLOROBENZYL) 1,7 DIMETHYL 1H IMIDAZO[2,1 F]PURINE 2,4(3H,8H) DIONE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; FIBRONECTIN; IM 412; IMIDAZOLE DERIVATIVE; LUCIFERASE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LUNG FIBROBLAST; LUNG FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL DIFFERENTIATION; CELL LINE; FIBROBLASTS; HUMANS; IMIDAZOLES; LUNG; PULMONARY FIBROSIS; PURINES; TRANSFORMING GROWTH FACTOR BETA;

EID: 77955845171     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.067     Document Type: Article

References (29)

1. Strieter R.M., Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009, 136:1364-1370.
2. Olson A.L., Swigris J.J., Lezotte D.C., Norris J.M., Wilson C.G., Brown K.K. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 2007, 176:277-284.
3. Gharaee-Kermani M., Hu B., Phan S.H., Gyetko M.R. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. Curr. Med. Chem. 2009, 16:1400-1417.
4. Scotton C.J., Chambers R.C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007, 132:1311-1321.
5. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
6. Neurohr C., Behr J. Diagnosis and therapy of interstitial lung diseases. Dtsch. Med. Wochenschr. 2009, 134:524-529.
7. Ponticos M., Holmes A.M., Shi-wen X., Leoni P., Khan K., Rajkumar V.S., Hoyles R.K., Bou-Gharios G., Black C.M., Denton C.P., Abraham D.J., Leask A., Lindahl G.E. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009, 60:2142-2155.
8. Chaudhary N.I., Roth G.J., Hilberg F., Muller-Quernheim J., Prasse A., Zissel G., Schnapp A., Park J.E. Inhibition of PDGF VEGF and FGF signaling attenuates fibrosis. Eur. Respir. J. 2007, 29:976-985.
9. Koli K., Myllarniemi M., Keski-Oja J., Kinnula V.L. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal. 2008, 10:333-342.
10. Antoniou K.M., Pataka A., Bouros D., Siafakas N.M. Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2007, 20:453-461.
11. Liu X., Wang W., Hu H., Tang N., Zhang C., Liang W., Wang M. Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells. Pharm. Res. 2006, 23:82-89.
12. Gaedeke J., Noble N.A., Border W.A. Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int. 2004, 66:112-120.
13. Zhang Y.E. Non-smad pathways in TGF-beta signaling. Cell Res. 2009, 19:128-139.
14. Araya J., Nishimura S.L. Fibrogenic reactions in lung disease. Annu. Rev. Pathol. 2010, 5:77-98.
15. Ma C.X., Hobday T.J., Jett J.R. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin. Proc. 2003, 78:1578-1579.
16. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 2007, 117:524-529.
17. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 2004, 85:47-64.
18. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., Pennathur S., Martinez F.J., Thannickal V.J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
19. Gu L., Zhu Y.J., Yang X., Guo Z.J., Xu W.B., Tian X.L. Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharmacol. Sin. 2007, 28:382-391.
20. Li F., Zeng B., Chai Y., Cai P., Fan C., Cheng T. The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis. Biochem. Biophys. Res. Commun. 2009, 386:289-293.
21. Hocevar B.A., Brown T.L., Howe P.H. TGF-beta induces fibronectin synthesis through a c-jun N-terminal kinase-dependent Smad4-independent pathway. EMBO J. 1999, 18:1345-1356.
22. Hashimoto S., Gon Y., Takeshita I., Matsumoto K., Maruoka S., Horie T. Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-jun-NH2-terminal kinase-dependent pathway. Am. J. Respir. Crit. Care Med. 2001, 163:152-157.
23. Hu Y., Peng J., Feng D., Chu L., Li X., Jin Z., Lin Z., Zeng Q. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein-1 in transforming growth factor-beta1-induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 2006, 184:33-42.
24. Caraci F., Gili E., Calafiore M., Failla M., La Rosa C., Crimi N., Sortino M.A., Nicoletti F., Copani A., Vancheri C. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol. Res. 2008, 57:274-282.
25. Kang J.S., Liu C., Derynck R. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol. 2009, 19:385-394.
26. Lawler S., Feng X.H., Chen R.H., Miko Maruoka E., Turck C.W., Prenner I., Derynck R. The type II transforming growth factor-β receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J. Biol. Chem. 1997, 272:14850-14859.
27. Callahan J.F., Burgess J.L., Fornwald J.A., Gaster L.M., Harling J.D., Harrington F.P., Heer J., Kwon C., Lehr R., Mathur A., Olson B.A., Weinstock J., Laping N.J. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J. Med. Chem. 2002, 45:999-1001.
28. Yano Y., Yoshida M., Hoshino S., Inoue K., Kida H., Yanagita M., Takimoto T., Hirata H., Kijima T., Kumagai T., Osaki T., Tachibana I., Kawase I. Anti-fibrotic effects of theophylline on lung fibroblasts. Biochem. Biophys. Res. Commun. 2006, 341:684-690.
29. Baraldi P.G., Preti D., Tabrizi M.A., Fruttarolo F., Romagnoli R., Zaid N.A., Moorman A.R., Merighi S., Varani K., Borea P.A. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists. J. Med. Chem. 2005, 48:4697-4701.